These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32669577)

  • 41. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.
    Chiron D; Pellat-Deceunynck C; Maillasson M; Bataille R; Jego G
    J Immunol; 2009 Oct; 183(7):4371-7. PubMed ID: 19734228
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol.
    Freyschmidt EJ; Alonso A; Hartmann G; Gissmann L
    Antivir Ther; 2004 Aug; 9(4):479-89. PubMed ID: 15456078
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytosine-phosphate-guanine oligodeoxynucleotides containing GACGTT motifs enhance the immune responses elicited by keyhole limpet hemocyanin antigen in dairy cattle.
    Chu CY; Lee SC; Liu SS; Lin YM; Shen PC; Yu C; Lee KH; Zhao X; Lee JW
    Nucleic Acid Ther; 2011 Oct; 21(5):323-32. PubMed ID: 21916610
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity.
    Yu C; An M; Jones E; Liu H
    Pharm Res; 2018 Feb; 35(3):56. PubMed ID: 29423660
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination.
    Ma R; Du JL; Huang J; Wu CY
    Biochem Biophys Res Commun; 2007 Sep; 361(2):537-42. PubMed ID: 17662694
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
    Wingender G; Garbi N; Schumak B; Jüngerkes F; Endl E; von Bubnoff D; Steitz J; Striegler J; Moldenhauer G; Tüting T; Heit A; Huster KM; Takikawa O; Akira S; Busch DH; Wagner H; Hämmerling GJ; Knolle PA; Limmer A
    Eur J Immunol; 2006 Jan; 36(1):12-20. PubMed ID: 16323249
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
    Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I
    J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro.
    Rothenfusser S; Hornung V; Ayyoub M; Britsch S; Towarowski A; Krug A; Sarris A; Lubenow N; Speiser D; Endres S; Hartmann G
    Blood; 2004 Mar; 103(6):2162-9. PubMed ID: 14630815
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Toll-like receptor 9 ligand blocks osteoclast differentiation through induction of phosphatase.
    Amcheslavsky A; Bar-Shavit Z
    J Bone Miner Res; 2007 Aug; 22(8):1301-10. PubMed ID: 17488193
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).
    Weeratna RD; Makinen SR; McCluskie MJ; Davis HL
    Vaccine; 2005 Nov; 23(45):5263-70. PubMed ID: 16081189
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Leishmanial CpG DNA nanovesicles: A propitious prophylactic approach against visceral leishmaniasis.
    Tiwari RK; Chandrakar P; Gupta CL; Sayyed U; Shekh R; Bajpai P
    Int Immunopharmacol; 2021 Jan; 90():107181. PubMed ID: 33249044
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The secretion of IL-6 by CpG-ODN-treated cancer cells promotes T-cell immune responses partly through the TLR-9/AP-1 pathway in oral squamous cell carcinoma.
    Ruan M; Thorn K; Liu S; Li S; Yang W; Zhang C; Zhang C
    Int J Oncol; 2014 Jun; 44(6):2103-10. PubMed ID: 24676671
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
    Roda JM; Parihar R; Carson WE
    J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CpG immunostimulatory sequences enhance contact hypersensitivity responses in mice.
    Akiba H; Satoh M; Iwatsuki K; Kaiserlian D; Nicolas JF; Kaneko F
    J Invest Dermatol; 2004 Sep; 123(3):488-93. PubMed ID: 15304088
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T cells.
    Gutjahr A; Papagno L; Nicoli F; Kanuma T; Kuse N; Cabral-Piccin MP; Rochereau N; Gostick E; Lioux T; Perouzel E; Price DA; Takiguchi M; Verrier B; Yamamoto T; Paul S; Appay V
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944257
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TLR9 ligand enhances proliferation of rat CD4+ T cell and modulates suppressive activity mediated by CD4+ CD25+ T cell.
    Chiffoleau E; Heslan JM; Heslan M; Louvet C; Condamine T; Cuturi MC
    Int Immunol; 2007 Feb; 19(2):193-201. PubMed ID: 17208927
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TLR9 agonist adsorbed to alum adjuvant prevents asthma-like responses induced by Blomia tropicalis mite extract.
    Nunes FPB; Alberca-Custódio RW; Gomes E; Fonseca DM; Yokoyama NH; Labrada A; Russo M
    J Leukoc Biol; 2019 Sep; 106(3):653-664. PubMed ID: 31329326
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Direct Engagement of TLR9 Ligand with T Helper Cells Leads to Cell Proliferation & Up-regulation of Cytokines.
    Sharma RK; Sehgal S; Sachdeva N; Kumar R; Gupta A
    Immunol Invest; 2019 Jan; 48(1):79-95. PubMed ID: 30239236
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release.
    Hong Z; Jiang Z; Liangxi W; Guofu D; Ping L; Yongling L; Wendong P; Minghai W
    Int Immunopharmacol; 2004 Feb; 4(2):223-34. PubMed ID: 14996414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.